Skip to main content

Table 1 Biodemographic and clinical characteristics of patients and controls

From: Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α

CharacteristicsCML patientsControls (n = 20)
TKI (n = 33)TKI + IFN-α (n = 8)
Demographic features
 Gender (%)
  Male18 (54.5)4 (50.0)7 (35.0)
  Female15 (45.5)4 (50.0)13 (65.0)
 Age (years)
  Median635058
  Range37–8434–6230–89
Clinical features
 Age at diagnosis (years)
  Median5042 
  Range24–7825–60 
 Time of disease (years)
  Median11.23.4 
  Range1.3–22.72.1–24.1 
 Scoring systems
  Sokal score(n = 32)(n = 7) 
  Low risk (%)13 (40.6)4 (57.1) 
  Intermediate risk (%)13 (40.6)1 (14.3) 
  High risk (%)6 (18.8)2 (28.6) 
 Euro score(n = 32)(n = 7) 
  Low risk (%)14 (43.8)5 (71.4) 
  Intermediate risk (%)17 (53.2)2 (28.6) 
  High risk (%)1 (3.0) 
 Eutos score(n = 33)(n = 7) 
  Low risk (%)27 (81.8)1 (14.3) 
  High risk (%)6 (18.2)6 (85.7) 
 Type of TKI
  Imatinib (%)26 (78.8)6 (75.0) 
  Nilotinib (%)1 (3.0)2 (25.0) 
  Dasatinib (%)2 (6.1) 
  Bosutinib (%)3 (9.1) 
  Ponatinib (%)1 (3.0)